PHP
ALXN

Parkman Healthcare Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Parkman Healthcare Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$5.72M – 100
2020
Q3 		$5.72M Buy
+50,000
New +$5.39M 1.52% 25

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Parkman Healthcare Partners's ALXN Position: Q4 2020 in Review

Parkman Healthcare Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 50,000 shares — an estimated $5.72M sold.

Parkman Healthcare Partners first reported a position in ALXN in Q3 2020 and held it in 1 quarter. The position peaked at $5.72M in Q3 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Parkman Healthcare Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 50,000 Alexion Pharmaceuticals shares in Q4 2020, an estimated $5.72M.
  • Parkman Healthcare Partners first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Parkman Healthcare Partners's Alexion Pharmaceuticals position peaked at $5.72M in Q3 2020.
  • 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.